ArticleClinical cancer drugs2018

Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models.

Anna R Schreiber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.